Table 3. Maximum estimated unit costs of activities pertaining to the prevention of mother-to-child transmission (PMTCT) of HIV, Namibia and Rwanda, 2009.
| Activity | Cost (US$)a |
|
|---|---|---|
| Namibia | Rwanda | |
| Testing and counselling | 21.56 | 9.99 |
| CD4+ cell count | 17.03 | 11.17 |
| Treatment and prophylaxis | ||
| NVP | 1.54 | 0.18 |
| 2 antiretrovirals for PMTCT prophylaxis | 25.62 | 63.91 |
| 3 antiretrovirals for PMTCT prophylaxis | 92.76 | 32.68 |
| 2006 WHO ART recommendations15 | 483.83 | 165.61 |
| 2010 WHO ART recommendations16 | ||
| Option A | 326.70 | 136.69 |
| Option B | 766.78 | 203.33 |
| SXT prophylaxis for the HIV-exposed infant | 48.11 | 16.64 |
| Family planning | 113.67 | 34.53 |
| Early infant diagnosis | 60.92 | 10.91 |
ART, antiretroviral therapy; HIV, human immunodeficiency virus; NVP, nevirapine; SXT, co-trimoxazole; US$, United States dollars; WHO, World Health Organization.
a Depending on the activity, the costs shown are per mother–infant pair, per woman, per individual or per infant.